[{"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-001", "question": "A 58-year-old man undergoes pancreaticoduodenectomy for a 2.5 cm pancreatic head adenocarcinoma. On postoperative day 3, his closed-suction drain has serous output of 25 mL/24 hours. Drain fluid amylase is 1,200 U/L (serum amylase 150 U/L). He is afebrile, hemodynamically stable, with soft abdomen and no leukocytosis. What is the most appropriate next step in management?", "options": ["Remove the drain", "Keep the drain and start octreotide", "Obtain contrast-enhanced CT of abdomen", "Keep the drain and discharge to home", "Return to operating room for exploration"], "answer": "A", "answer_index": 0, "explanation": "The 2016 ISGPS update defines a 'biochemical leak' as drain fluid amylase >3x serum on POD 1-3 with output <30 mL/day and no clinical sequelae, which can be managed by drain removal. Grade B fistula requires output >30 mL/day or clinical impact. The high amylase alone does not mandate retention if output remains low and the patient is clinically well.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: POD3, closed-suction drain, serous output 25 mL/24h (low), drain amylase 1200 U/L (8x serum), patient afebrile, hemodynamically stable, soft abdomen, no leukocytosis. These findings meet the ISGPS definition of a biochemical leak (formerly grade A fistula), where the low-volume, clinically silent high-amylase output is managed by drain removal. The item is logically valid and medically accurate, aligning with modern postoperative pancreatic fistula (POPF) classification and management. The keyed answer (A) is uniquely defensible. Alternatives are worse: B/C/E are for symptomatic or higher-output leaks; D is premature discharge with a drain in place. Minimal fix: None required; the item is clear and accurate as written.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: POD3, closed-suction drain, serous output 25 mL/24h (low), drain amylase 1200 U/L (8x serum), patient afebrile, hemodynamically stable, soft abdomen, no leukocytosis. These findings meet the ISGPS definition of a biochemical leak (formerly grade A fistula), where the low-volume, clinically silent high-amylase output is managed by drain removal. The item is logically valid and medically accurate, aligning with modern postoperative pancreatic fistula (POPF) classification and management. The keyed answer (A) is uniquely defensible. Alternatives are worse: B/C/E are for symptomatic or higher-output leaks; D is premature discharge with a drain in place. Minimal fix: None required; the item is clear and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-002", "question": "A 65-year-old man is diagnosed with high-grade T1 urothelial carcinoma of the bladder, 3 cm solitary lesion without carcinoma in situ. His EORTC risk score is 8. He is scheduled to begin intravesical BCG immunotherapy. What is the optimal evidence-based regimen?", "options": ["Induction only (6 weekly instillations)", "Induction plus 1-year maintenance", "Induction plus 3-year maintenance using Tice strain", "Induction plus 3-year maintenance using Connaught strain with first maintenance dose at 8 weeks", "Induction plus 2-year maintenance"], "answer": "D", "answer_index": 3, "explanation": "An EORTC score of 8 classifies high-risk disease mandating 3-year maintenance BCG. The Connaught strain demonstrates superior recurrence-free survival compared to Tice strain in meta-analyses. Maintenance must commence 8 weeks after induction completion. This regimen reduces recurrence by 37% compared to 1-year maintenance and is the standard of care for high-risk patients.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: high-grade T1, solitary 3 cm lesion, no CIS, EORTC score 8 (high-risk). The vignette clearly defines a high-risk non-muscle-invasive bladder cancer patient, for whom guidelines (AUA/EAU) recommend induction BCG followed by maintenance therapy. The optimal evidence-based regimen for high-risk disease is induction plus 3-year maintenance. However, the key (D) incorrectly specifies the Connaught strain and an 8-week start for the first maintenance dose. While 3-year maintenance is correct, current major guidelines (AUA, EAU, NCCN) do not endorse one BCG strain over another as superior, and the standard maintenance schedule begins at 3 months (not 8 weeks), making option D inaccurate. Option C is the most defensible best answer, as it correctly states 'Induction plus 3-year maintenance' without the incorrect strain/schedule specifics. Main logical issue: a unique best answer exists (3-year maintenance), but the provided key is not it. Main medical accuracy issue: the rationale contains outdated/contradicted claims about strain superiority and maintenance timing. Minimal fix: Change the key to C and update the rationale to reflect guideline-concordant 3-year maintenance without specifying strain or non-standard timing.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \t\n  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: high-grade T1, solitary 3 cm lesion, no CIS, EORTC score 8 (high-risk). The vignette clearly defines a high-risk non-muscle-invasive bladder cancer patient, for whom guidelines (AUA/EAU) recommend induction BCG followed by maintenance therapy. The optimal evidence-based regimen for high-risk disease is induction plus 3-year maintenance. However, the key (D) incorrectly specifies the Connaught strain and an 8-week start for the first maintenance dose. While 3-year maintenance is correct, current major guidelines (AUA, EAU, NCCN) do not endorse one BCG strain over another as superior, and the standard maintenance schedule begins at 3 months (not 8 weeks), making option D inaccurate. Option C is the most defensible best answer, as it correctly states 'Induction plus 3-year maintenance' without the incorrect strain/schedule specifics. Main logical issue: a unique best answer exists (3-year maintenance), but the provided key is not it. Main medical accuracy issue: the rationale contains outdated/contradicted claims about strain superiority and maintenance timing. Minimal fix: Change the key to C and update the rationale to reflect guideline-concordant 3-year maintenance without specifying strain or non-standard timing.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-003", "question": "A 72-year-old woman with metastatic melanoma on combination ipilimumab/nivolumab develops six watery stools daily. Laboratory studies show AST 180 U/L (upper limit of normal 40), ALT 220 U/L, and normal bilirubin. Colonoscopy reveals ulcerative colitis-like changes. What is the next step in management?", "options": ["Start prednisone 1 mg/kg plus infliximab 5 mg/kg", "Start prednisone 1 mg/kg plus vedolizumab 300 mg", "Start prednisone 1 mg/kg; if no improvement in 3-5 days add vedolizumab", "Hold immunotherapy and observe", "Start mycophenolate mofetil 1 g twice daily"], "answer": "C", "answer_index": 2, "explanation": "Grade 3 immune-related colitis with concurrent grade 2 hepatitis requires high-dose steroids (1-2 mg/kg prednisone). Infliximab is contraindicated in grade ≥2 hepatitis due to hepatotoxicity risk. Vedolizumab is the preferred second-line agent for steroid-refractory colitis without hepatic toxicity, but should be added only after 3-5 days of steroid failure rather than empirically.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: metastatic melanoma on ipilimumab/nivolumab, grade 3 colitis (6 watery stools/day, ulcerative colitis-like changes on colonoscopy), concurrent grade 2 hepatitis (elevated AST/ALT, normal bilirubin). The combination of steroid-refractory colitis and hepatitis makes infliximab (hepatotoxic) contraindicated and vedolizumab the preferred second-line agent, but guidelines recommend adding it only after 3-5 days of high-dose steroids without improvement. Main logical issue: None. Main medical accuracy issue: None; aligns with current ASCO/NCCN guidelines for immune-related adverse events. Minimal fix: None required; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\": \n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: metastatic melanoma on ipilimumab/nivolumab, grade 3 colitis (6 watery stools/day, ulcerative colitis-like changes on colonoscopy), concurrent grade 2 hepatitis (elevated AST/ALT, normal bilirubin). The combination of steroid-refractory colitis and hepatitis makes infliximab (hepatotoxic) contraindicated and vedolizumab the preferred second-line agent, but guidelines recommend adding it only after 3-5 days of high-dose steroids without improvement. Main logical issue: None. Main medical accuracy issue: None; aligns with current ASCO/NCCN guidelines for immune-related adverse events. Minimal fix: None required; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-004", "question": "A 45-year-old man with necrotizing pancreatitis is now 3 weeks from disease onset. Contrast-enhanced CT demonstrates a 9-cm walled-off necrosis in the lesser sac with a mature, well-defined wall. ERCP confirms disconnected pancreatic duct syndrome. He is febrile to 38.5°C with WBC 15,000 cells/µL. What is the definitive management?", "options": ["Immediate percutaneous catheter drainage", "Endoscopic ultrasound-guided cystgastrostomy now", "Surgical cystgastrostomy with necrosectomy now", "Delay intervention until 4 weeks then proceed endoscopically", "Continue antibiotics and observe"], "answer": "C", "answer_index": 2, "explanation": "The 2020 revised Atlanta guidelines permit intervention when WON demonstrates a mature wall, eliminating the mandatory 4-week wait. Disconnected pancreatic duct syndrome is a surgical indication because endoscopic drainage alone is associated with 40% recurrence. Surgical cystgastrostomy with necrosectomy definitively addresses both the necrosis and ductal disruption, reducing recurrence to <10%.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: walled-off necrosis (WON) with mature wall at 3 weeks, disconnected pancreatic duct syndrome (DPDS), fever, leukocytosis. The vignette describes infected WON requiring drainage. Current guidelines (e.g., revised Atlanta, AGA) state endoscopic step-up approach (transmural drainage ± necrosectomy) is first-line for infected WON, even with DPDS, with surgery reserved for endoscopic failure. Option B (EUS-guided cystgastrostomy now) is the guideline-supported definitive management, not immediate surgery (C). The keyed answer (C) is not the single best answer. Main logical issue: key mismatch. Main medical accuracy issue: overstates surgical indication; endoscopic drainage is standard initial definitive therapy. Minimal fix: Change key to B and adjust rationale to reflect endoscopic-first step-up approach for infected WON with DPDS.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: walled-off necrosis (WON) with mature wall at 3 weeks, disconnected pancreatic duct syndrome (DPDS), fever, leukocytosis. The vignette describes infected WON requiring drainage. Current guidelines (e.g., revised Atlanta, AGA) state endoscopic step-up approach (transmural drainage ± necrosectomy) is first-line for infected WON, even with DPDS, with surgery reserved for endoscopic failure. Option B (EUS-guided cystgastrostomy now) is the guideline-supported definitive management, not immediate surgery (C). The keyed answer (C) is not the single best answer. Main logical issue: key mismatch. Main medical accuracy issue: overstates surgical indication; endoscopic drainage is standard initial definitive therapy. Minimal fix: Change key to B and adjust rationale to reflect endoscopic-first step-up approach for infected WON with DPDS.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-005", "question": "A 58-year-old kidney transplant recipient (deceased donor, 8 months post-transplant) presents with rising creatinine from 1.2 to 2.1 mg/dL. Plasma BK virus PCR is 18,000 copies/mL. Allograft biopsy shows Banff class B BK virus nephropathy. Current immunosuppression: tacrolimus 5 mg twice daily (trough 8 ng/mL), mycophenolate mofetil 1000 mg twice daily, prednisone 5 mg daily. What is the first immunosuppression modification?", "options": ["Reduce tacrolimus dose by 50%", "Reduce mycophenolate mofetil by 50%", "Discontinue tacrolimus and switch to cyclosporine", "Discontinue mycophenolate mofetil completely", "Reduce prednisone to 2.5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "For BK viremia >10,000 copies/mL with Banff class B nephropathy, first-line therapy is mycophenolate dose reduction by 50% or complete discontinuation. Tacrolimus reduction is second-line if viremia persists after 2-4 weeks. This sequence preserves tacrolimus (the cornerstone immunosuppressant) while reducing the antiproliferative agent that most impairs viral clearance. Steroids should not be reduced initially.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: BK virus nephropathy (Banff class B) with high viral load (18,000 copies/mL) in a kidney transplant recipient on tacrolimus, mycophenolate, and low-dose prednisone. Main logical issue: The keyed answer (B, reduce mycophenolate by 50%) contradicts standard management guidelines, which prioritize reducing or discontinuing the calcineurin inhibitor (tacrolimus) first to enhance viral clearance, as mycophenolate has less impact on BK virus-specific immunity. A unique best answer exists (A, reduce tacrolimus dose by 50%), but the provided key is incorrect. Main medical accuracy issue: The rationale incorrectly prioritizes mycophenolate reduction over tacrolimus reduction, which is not aligned with current consensus. Minimal fix: Change the key to A and update the explanation to reflect that initial immunosuppression reduction for BK virus nephropathy typically targets the calcineurin inhibitor.\",\n    \"medical_accuracy_score\":  \"2\",\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: BK virus nephropathy (Banff class B) with high viral load (18,000 copies/mL) in a kidney transplant recipient on tacrolimus, mycophenolate, and low-dose prednisone. Main logical issue: The keyed answer (B, reduce mycophenolate by 50%) contradicts standard management guidelines, which prioritize reducing or discontinuing the calcineurin inhibitor (tacrolimus) first to enhance viral clearance, as mycophenolate has less impact on BK virus-specific immunity. A unique best answer exists (A, reduce tacrolimus dose by 50%), but the provided key is incorrect. Main medical accuracy issue: The rationale incorrectly prioritizes mycophenolate reduction over tacrolimus reduction, which is not aligned with current consensus. Minimal fix: Change the key to A and update the explanation to reflect that initial immunosuppression reduction for BK virus nephropathy typically targets the calcineurin inhibitor.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-006", "question": "A 62-year-old man with metastatic melanoma receives axicabtagene ciloleucel. On day 7 post-infusion, he develops confusion, expressive aphasia, and asterixis. He has a low-grade fever (37.8°C) only. ICE score is 8/10. EEG demonstrates triphasic waves. Brain MRI is normal. What is the immediate management?", "options": ["Tocilizumab 8 mg/kg intravenously once", "Dexamethasone 10 mg intravenously every 6 hours", "Methylprednisolone 1 g intravenously daily", "Tocilizumab plus dexamethasone 10 mg every 6 hours", "Supportive care with scheduled haloperidol"], "answer": "B", "answer_index": 1, "explanation": "An ICE score of 8 indicates grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS), which requires dexamethasone 10 mg IV q6h. Tocilizumab is indicated for cytokine release syndrome (CRS), not ICANS, and is unnecessary for grade 1 CRS. High-dose methylprednisolone is reserved for grade ≥3 ICANS. The EEG findings are characteristic but do not escalate management beyond standard ICANS algorithms.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Day 7 post-axicabtagene ciloleucel with confusion, aphasia, asterixis, ICE score 8/10 (grade 2 ICANS), triphasic waves on EEG, normal MRI, and only low-grade fever (grade 1 CRS). The unique best answer is D (Tocilizumab plus dexamethasone), as current NCCN/ASCT guidelines recommend adding tocilizumab for concurrent grade 1 CRS with grade 2 ICANS to prevent CRS escalation, which is a critical nuance. The keyed answer B (dexamethasone alone) is incorrect per these guidelines, as it omits tocilizumab for the co-present CRS. The item is medically accurate but miskeyed. Minimal fix: Change the correct answer key to D.\",\n  \"medical_accuracy_score\":  \"4\",\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Day 7 post-axicabtagene ciloleucel with confusion, aphasia, asterixis, ICE score 8/10 (grade 2 ICANS), triphasic waves on EEG, normal MRI, and only low-grade fever (grade 1 CRS). The unique best answer is D (Tocilizumab plus dexamethasone), as current NCCN/ASCT guidelines recommend adding tocilizumab for concurrent grade 1 CRS with grade 2 ICANS to prevent CRS escalation, which is a critical nuance. The keyed answer B (dexamethasone alone) is incorrect per these guidelines, as it omits tocilizumab for the co-present CRS. The item is medically accurate but miskeyed. Minimal fix: Change the correct answer key to D.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}]